According to Daniel O’Day, Chairman & CEO, Gilead Sciences, “In the U.S., the same government price of $390 per vial will apply. Because of the way the U.S. system is set up and the discounts that government healthcare programs expect, the price for U.S. private insurance companies, will be $520 per vial. At the level we have priced remdesivir and with government programs in place, along with additional Gilead assistance as needed, we believe all patients will have access.”
Category Archives: AZBio News
FDA Approves First-Of-Its-Kind Percept™ PC Neurostimulator with BrainSense™ Technology
Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals
for More Personalized, Data-Driven TreatmentContinue reading
Dr. Joann Sweasy Named Director of University of Arizona Cancer Center
Dr. Sweasy will serve as director of the only Arizona-based National Cancer Institute-designated Comprehensive Cancer Center, as well as UArizona’s chief adviser on cancer-related matters and principal investigator of the NCI Cancer Center Support Grant.Continue reading
The MedTech Conference to Go Virtual for 2020
“The show will go on!” says AdvaMed CEO Scott WhitakerContinue reading
C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19
Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App.
TUCSON, Ariz., June 23, 2020 — As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes. Health care professionals use drugs in novel ways as a potential life-saving intervention when no specific approved therapies are available. However, without the ability to share these experiences in a systematic manner, the clinical and research communities cannot benefit from lessons learned.Continue reading
NIH halts clinical trial of hydroxychloroquine
Study shows treatment does no harm, but provides no benefitContinue reading
HTG Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel
Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive LymphomasContinue reading
Cancer Prevention Pharmaceuticals Submits EU Marketing Authorization Application for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
TUCSON, Arizona, June 18, 2020 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP).Continue reading
Governor Ducey Announces Enhanced COVID-19 Action Plan
Governor Ducey, Dr. Christ, Maj. Gen McGuire provided an Arizona COVID-19 briefing on June 17, 2020. Governor Ducey reminded everyone of Three Key Messages for all Arizonans:
- You are safest at home.
- If you must go out, physically distance.
- If you can not, Wear A Mask.
Executive Order 40 includes that “4. Notwithstanding directives in Executive Order 2020-36, Stay Healthy, Return Smarter, Return Stronger, regarding A.R.S. § 26-307, a county, city or town may, based on conditions in its jurisdiction, adopt policies regarding the wearing of face coverings in public for the purpose of mitigating the spread of COVID-19. Any enforcement of such a policy shall focus first on educating and working to promote best practices to accomplish the goal of mitigation. An individual shall be notified of the provisions of this order or any policy adopted by a county, city or town and given an opportunity to comply prior to any enforcement action being taken.”
Two NAU research centers receive Flinn Foundation funding to support COVID-19 response
Grants to support testing of vaccines and treatments for the coronavirus in NAU’s Pathogen and Microbiome Institute (PMI) and disease-intervention modeling in the Center for Health Equity Research (CHER)Continue reading